En raison de la diffusion incontrôlée sur le e-commerce, la sécurité et l’alternative légale aux stupéfiants habituels, les nouvelles substances psychoactives (NPS), d’apparition récente (2008), sont au cœur des phénomènes récents d’addiction et de décès mal expliqués. Au-delà des différents défis dans nos sociétés (prévention, législation), la capacité d’identifier les NPS dans des échantillons biologiques pour caractériser leur utilisation, présente de nombreux challenges analytiques. L’objectif principal de cette thèse a été de collecter des échantillons biologiques (sang, urine, cheveux) provenant de cas d’exposition à des NPS et d’y caractériser les substances présentes à l’aide de méthodes analytiques originales, dans le but d’enrichir les librairies de spectres de masse et d’améliorer, en conséquence, la détection de la consommation de NPS. En particulier, il s’agissait d’augmenter la fenêtre de détection de la prise de NPS en se focalisant sur les métabolites qui sont, le plus souvent, les produits majeurs d’élimination. Le développement analytique, par chromatographie liquide ultra haute performance couplée à la spectrométrie de masse en tandem (UHPLC-MS/MS), a demandé plusieurs mois d’optimisation afin d’obtenir une méthode robuste, exhaustive et sensible. Actuellement, la librairie de spectres MS comporte 114 NPS et est mise à jour régulièrement. A la suite de ce développement, ma thèse a porté sur l’étude de cas d’intoxication vus au service des urgences du CHU de Strasbourg, mais aussi en médecine légale, avec des situations de décès et d’identification de produits inconnus provenant de saisies (poudres et cristaux). Il a également été nécessaire de développer des outils analytiques complémentaires, tels que la caractérisation de métabolite(s) par étude sur microsomes hépatiques humains (HLMs), et l’utilisation de la spectroscopie par résonance magnétique nucléaire (RMN) afin d’identifier avec certitude certains composés et de déterminer leur degré de pureté. Les outils analytiques développés et la stratégie mise en place ont permis la rédaction de 18 publications, ainsi que l’agencement de nombreuses collaborations. / Due to the uncontrolled spread on the Internet and their legal alternative to usual drugs, the new psychoactive substances (NPS), recently appeared (2008), are at the center of recent phenomena of addiction and badly explained deaths. Beyond different challenges in our societies (prevention, legislation), the ability to identify NPS in biological samples, in order to characterize their use, presents many analytical challenges. The main objective of this thesis was to collect biological samples (blood, urine, hair) from cases of exposure to NPS and to characterize the substances present using original analytical methods, in order to enlarge the libraries of mass spectra and improve, as a result, the detection of NPS consumption. In particular, it was intended to increase the detection sensitivity of NPS intake by focusing on the metabolites that are often the major products of elimination. This analytical development, by ultra-high liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS), required several months of optimization in order to obtain a robust, exhaustive and sensitive method. At present, the mass spectra database has 114 NPS and is regularly updated. Thereafter, ma thesis focused on the study of cases of intoxication observed in the emergency department of Strasbourg, but also in legal medicine with situations of deaths and identification of unknown products collected from seizures (powders and crystals). It has also been necessary to implement complementary analytical tools, such as the characterization of metabolites by human liver microsomes (HLMs), and the use of nuclear magnetic resonance (NMR) spectroscopy to accurately identify the compounds and establish their purity degrees. The analytical tools developed, and the strategy adopted, allowed the writing of 18 publications, as well as the setting up of numerous collaborations.

Résumé confidentiel / Résumé confidentiel

Modern separation and spectrometric techniques for biological sample lipidom investigation Due recent progress in field of mass spectrometry the lipidomics, part of metabolomics, is increasing its importance for broad fields of biological study. The aim of this study is to test the lipid extraction techniques and to optimize the preseparation and separation of lipids suitable for mass spectrometry detection. The fragmentation patterns of four, the most abundant lipid classes of glycerolipids (PC, PE, TG, DG), were acquired for the proposed system. These patterns were compared with literature. The most appropriate method for extraction was declared technique according Folch based on methanol and chloroform solution. The preseparation due SPE method is very useful tool for lipid determination. The optimized were focused to reach higher recovery especially in polar lipid fraction. Proposed HPLC system is based on methanol with ammonium buffer, water and isopropanol. The testing was done on three columns with different type of sorbents (Gemini, Syncronis and Kinetex). The separation was evaluated according mass spectrometer response, shape and wide of particular analytes peaks. Composition contains 20% of water was determinate as the best and also the best separation was achieved by Kinetex column. The proposed...

A venlafaxina (VEN), em razão de sua eficácia e brandos efeitos adversos, tem sido um dos antidepressivos mais prescritos no tratamento da depressão e ansiedade. Neste trabalho, um método analítico empregando as técnicas MISPE miniaturizada e cromatografia líquida acoplada à espectrometria de massas em Tandem, foi utilizado para a determinação de VEN e seus principais metabólitos em amostras de plasma para fins de monitorização terapêutica. A fase MIP foi sintetizada via polimerização radicalar por precipitação, fazendo uso de VEN (molécula molde), ácido metacrílico (monômero funcional), etileno glicol dimetacrilato, (reagente reticulante) e 2,2 azobisisobutironitrila (iniciador radicalar) em tolueno (solvente). Para controle utilizou-se o polímero não impresso (NIP), sintetizado por procedimento análogo ao do MIP, porém sem o uso da molécula molde. A caracterização química e estrutural dos polímeros foi realizada por espectroscopia no infravermelho com transformada de fourier e microscopia eletrônica de varredura. A otimização das variáveis de MISPE miniaturizada favoreceu a detectabilidade analítica e diminuiu o efeito de memória. As extrações realizadas com MIP apresentaram taxa de recuperação de 84% para VEN e de 2-28% para os antidepressivos (clorpromazina, fluoxetina, clomipramina, imipramina e sertralina). O polímero não impresso apresentou baixa recuperação para a VEN (taxa de recuperação: 49%) e para os demais antidepressivos (taxas de recuperação menores que 40%). Estes experimentos comprovam a seletividade da fase MIP desenvolvida. O método padronizado apresentou linearidade na faixa de 3 a 700 ng mL-1 para VEN, 5 a 700 ng mL-1 para O-desmetilvenlafaxina (ODV) e de 3 a 500 ng mL-1 para N-desmetilvenlafaxina (NDV), precisão com coeficientes de variação menores que 15% e exatidão com valores de erro padrão relativo na faixa de -11,8 a 16,01 %. As concentrações correspondentes aos limites inferiores de quantificação para VEN (3 ng mL-1) e ODV ( 5 ng mL-1) foram inferiores aos intervalos terapêuticos preconizados. O método desenvolvido, quando comparado a aos métodos da literatura para determinação de VEN e metabolitos, apresentou maior seletividade, menor consumo de amostra e de solventes orgânicos e permitiu a reutilização da fase extratora. Segundo os parâmetros de validação analítica avaliados e amostras de pacientes em terapia com VEN analisadas, o método proposto é adequado para determinação de VEN, ODV e NDV em amostras de plasma para fins de monitorização terapêutica. / Venlafaxine elicits a small number of adverse effects, so it is one of the most frequently prescribed drugs to treat major depression, generalized anxiety, and social anxiety disorders in adults. In this study, venlafaxine (VEN), O-desmethylvenlafaxine (ODV), and N-desmethylvenlafaxine (NDV) were pre-concentrated with the aid of miniaturized SPE based on MIPs as extraction phase. MIPs are synthetic polymers with cavities specifically designed to hold a target molecule or structurally similar compounds. The molecularly imprinted polymers were prepared by addition of VEN, metacrylic acid (MAA, monomer), ethylene glycol dimethacrylate (EGDMA, cross-linker), and 2,2-azobisisobutyronitrile (AIBN, initiator) to toluene (solvent). The non-imprinted polymer (NIP), used for comparison, was also synthesized by following exactly the same procedure, but excluding the template VEN from the formulation. The polymer was characterized by Fourier transform infrared spectroscopy and scanning electron microscopy (SEM). Optimization of the MIP phase extraction variables favored miniaturized analytical detectability and reduced the memory effect. The extractions performed with the synthesized MIP showed recovery rate of 84% for VEN and 2-28% for other antidepressants (chlorpromazine, fluoxetine, clomipramine, imipramine, and sertraline). The non-imprinted polymer provided low recovery of VEN (recovery rate: 49%) and other antidepressants (recovery rates lower than 40%). These experiments demonstrated the selectivity of the developed MIP phase. The standardized method was linear in the range of 300 - 700 ng mL-1 for VEN, 5-700 ng mL-1 for ODV, and 3 to 500 ng mL-1 for NDV. Precision had coefficients of variation smaller than 15%; the accuracy standard error values ranged from -11.8 to 16.01%. Compared with literature methods, the developed method was more selective for determination of VEN and metabolites, required lower consumption of sample and organic solvents, and enabled reuse of the extraction phase. According to the assessed analytical validation parameters and to the analysis of samples obtained from patients undergoing therapy with VEN, the proposed method is suitable to determine VEN, NDV, and ODV in plasma samples for therapeutic drug monitoring.

Esta tese foi dividida em três capítulos. O capítulo I descreve o desenvolvimento do método Column switching UHPLC-MS/MS para a determinação simultaneamente de fármacos psicotrópicos em amostras de plasma de pacientes esquizofrênicos. A politerapia é uma prática comum no tratamento da esquizofrenia. Portanto, a monitorização terapêutica destes fármacos tem sido realizada para o ajuste das doses e individualização da terapia farmacológica. O método Column switching UHPLC-MS/MS apresentou linearidade na faixa de concentração de 0,025 a 1,25 ng mL-1 com R2 acima de 0,9950 e a falta de teste de ajuste (p > 0,05); precisão com coeficientes de variação inferiores a 12% e exatidão com erro padrão relativo inferior a 14%. Este método foi aplicado com sucesso para determinação de fármacos em amostras de plasma de pacientes esquizofrênicos para fins de monitorização terapêutica. No capítulo II, o desempenho cromatográfico de colunas C18 superficialmente e totalmente porosas com diferentes tamanhos de partícula foi avaliado para a análise de fármacos psicotrópicos por LC-MS/MS e LC-DAD. Com o sistema LC-MS/MS foram avaliados os seguintes parâmetros cromatográficos: altura do prato reduzido vs velocidade linear reduzida, impedância vs velocidade linear reduzida, tempo da corrida cromatográfica vs vazão, pressão vs vazão, resolução, capacidade de pico, assimetria e fator de retenção. Já com o sistema LC-DAD foram avaliados a hidrofobicidade, atividade silanol e impurezas metálicas também foram avaliadas. As colunas com superfície carregada apresentaram maior eficiência cromatográfica para os fármacos em sua forma ionizada. Já as colunas com partículas menores que 2 µm (Cortecs 1,6 µm, Acquity 1,7 µm, e Kinetex 1,7 µm) apresentaram maior eficiência cromatográfica para os fármacos na forma parcialmente ionizada. Os modelos matemáticos gerados foram capazes de prever a pressão e o tempo da corrida cromatográfica em diferentes vazões para todas as colunas. Considerando a eficiência, impedância, resolução, capacidade de pico, fator de retenção e hidrofobicidade, as colunas Cortecs 1,6 µm e Acquity 1,7 µm apresentaram melhor desempenho durante a análise dos fármacos em amostra de plasma. O capítulo III descreve o desenvolvimento e validação dos métodos SPME-UHPLC-MS/MS e Bio-SPME-Nano-ESI-MS/MS para a determinação dos endocanabinóides (AEA e 2-AG) em amostras biológicas. Para a otimização do processo SPME foram avaliadas as fases SPME (C18, C30 e HLB) e os solventes para dessorção (metanol, acetonitrila e isopropanol). Os aditivos modificadores de matriz, como cloridrato de guanidina, ácido trifluoroacético e acetonitrila foram avaliados por planejamento experimental. Os métodos SPME-UHPLC-MS/MS e Bio-SPME-Nano-ESI-MS/MS, com a fase HLB biocompatível, apresentaram para ambos endocanabinóides valores de LOQs de 1 ng mL-1 e 50 ng mL-1, respectivamente. O método Bio-SPME-Nano-ESI-MS/MS permitiu o direto acoplamento da fibra SPME ao espectrômetro de massas via dessorção/ionização nanoeletrospray que resultou em rápida determinação quantitativa dos endocanabinóides em amostras biológicas. / This thesis is divided into three chapters. Chapter I describes the development of a column switching UHPLCMS/MS method to determine psychotropic drugs in schizophrenic patients plasma samples simultaneously. Polytherapy is a common practice in schizophrenia treatment. Therefore, therapeutic drug monitoring has been applied to adjust doses and to customize pharmacological therapy. The column switching UHPLCMS/MS method developed here is linear at concentrations ranging from 0.025 to 1.25 ng mL-1 with R2 above 0.9950 and presents lack of fit test (p > 0.05), precision with coefficients of variation lower than 12%, and accuracy with relative standard error lower than 14%. This method was successfully applied to determine drugs in schizophrenic patients plasma samples for therapeutic drug monitoring. In chapter II, the chromatographic performance of C18 superficially porous columns and of C18 fully porous columns with different particle sizes were evaluated for analysis of psychotropic drugs by LC-MS/MS and LC-DAD. Within the LC-MS/MS system, the following chromatographic parameters were assessed: reduced plate height vs reduced linear velocity, impedance vs reduced linear velocity, chromatographic run time vs flow rate, backpressure vs flow rate, resolution, peak capacity, asymmetry, and retention factor. Within the LC-DAD system, hydrophobicity, silanol activity, and metal impurities were also examined. Columns with charged surface displayed improved chromatographic efficiency for drugs in the ionized form. Columns with particles smaller than 2 µm (Cortecs 1.6 µm, Acquity 1.7 µm, and Kinetex 1.7 µm) presented higher chromatographic efficiency for the drugs, which were in their partially ionized form. The generated mathematical models were able to predict the backpressure and the chromatographic run time at different flow rates for all the columns. Considering efficiency, impedance, resolution, peak capacity, retention factor, and hydrophobicity, columns Cortecs 1.6 µm and Acquity 1.7 µm provided the best performance during analysis of drugs in plasma samples. Chapter III describes the development and validation of the SPME-UHPLC-MS/MS and the Bio-SPME-Nano-ESI-MS/MS methods for determination of endocannabinoids (AEA and 2-AG) in biological samples. To optimize the SPME process, SPME coatings (C18, C30, and HLB) and solvents for desorption (methanol, acetonitrile, and isopropanol) were evaluated. Matrix modifier additives, such as guanidine hydrochloride, trifluoroacetic acid, and acetonitrile, were assessed by experimental design. The SPME-UHPC-MS/MS and the Bio-SPME-Nano-ESI-MS/MS methods with HLB biocompatible coating provided LOQ values of 1 ng mL-1 and 50 ng mL-1, respectively, for both endocannabinoids. The Bio-SPME-Nano-ESI-MS/MS method allowed direct coupling of SPME fibers to the mass spectrometer by desorption/ionization nanoelectrospray, which resulted in rapid quantitative determinations of endocannabinoids in biological samples.

A venlafaxina (VEN), em razão de sua eficácia e brandos efeitos adversos, tem sido um dos antidepressivos mais prescritos no tratamento da depressão e ansiedade. Neste trabalho, um método analítico empregando as técnicas MISPE miniaturizada e cromatografia líquida acoplada à espectrometria de massas em Tandem, foi utilizado para a determinação de VEN e seus principais metabólitos em amostras de plasma para fins de monitorização terapêutica. A fase MIP foi sintetizada via polimerização radicalar por precipitação, fazendo uso de VEN (molécula molde), ácido metacrílico (monômero funcional), etileno glicol dimetacrilato, (reagente reticulante) e 2,2 azobisisobutironitrila (iniciador radicalar) em tolueno (solvente). Para controle utilizou-se o polímero não impresso (NIP), sintetizado por procedimento análogo ao do MIP, porém sem o uso da molécula molde. A caracterização química e estrutural dos polímeros foi realizada por espectroscopia no infravermelho com transformada de fourier e microscopia eletrônica de varredura. A otimização das variáveis de MISPE miniaturizada favoreceu a detectabilidade analítica e diminuiu o efeito de memória. As extrações realizadas com MIP apresentaram taxa de recuperação de 84% para VEN e de 2-28% para os antidepressivos (clorpromazina, fluoxetina, clomipramina, imipramina e sertralina). O polímero não impresso apresentou baixa recuperação para a VEN (taxa de recuperação: 49%) e para os demais antidepressivos (taxas de recuperação menores que 40%). Estes experimentos comprovam a seletividade da fase MIP desenvolvida. O método padronizado apresentou linearidade na faixa de 3 a 700 ng mL-1 para VEN, 5 a 700 ng mL-1 para O-desmetilvenlafaxina (ODV) e de 3 a 500 ng mL-1 para N-desmetilvenlafaxina (NDV), precisão com coeficientes de variação menores que 15% e exatidão com valores de erro padrão relativo na faixa de -11,8 a 16,01 %. As concentrações correspondentes aos limites inferiores de quantificação para VEN (3 ng mL-1) e ODV ( 5 ng mL-1) foram inferiores aos intervalos terapêuticos preconizados. O método desenvolvido, quando comparado a aos métodos da literatura para determinação de VEN e metabolitos, apresentou maior seletividade, menor consumo de amostra e de solventes orgânicos e permitiu a reutilização da fase extratora. Segundo os parâmetros de validação analítica avaliados e amostras de pacientes em terapia com VEN analisadas, o método proposto é adequado para determinação de VEN, ODV e NDV em amostras de plasma para fins de monitorização terapêutica. / Venlafaxine elicits a small number of adverse effects, so it is one of the most frequently prescribed drugs to treat major depression, generalized anxiety, and social anxiety disorders in adults. In this study, venlafaxine (VEN), O-desmethylvenlafaxine (ODV), and N-desmethylvenlafaxine (NDV) were pre-concentrated with the aid of miniaturized SPE based on MIPs as extraction phase. MIPs are synthetic polymers with cavities specifically designed to hold a target molecule or structurally similar compounds. The molecularly imprinted polymers were prepared by addition of VEN, metacrylic acid (MAA, monomer), ethylene glycol dimethacrylate (EGDMA, cross-linker), and 2,2-azobisisobutyronitrile (AIBN, initiator) to toluene (solvent). The non-imprinted polymer (NIP), used for comparison, was also synthesized by following exactly the same procedure, but excluding the template VEN from the formulation. The polymer was characterized by Fourier transform infrared spectroscopy and scanning electron microscopy (SEM). Optimization of the MIP phase extraction variables favored miniaturized analytical detectability and reduced the memory effect. The extractions performed with the synthesized MIP showed recovery rate of 84% for VEN and 2-28% for other antidepressants (chlorpromazine, fluoxetine, clomipramine, imipramine, and sertraline). The non-imprinted polymer provided low recovery of VEN (recovery rate: 49%) and other antidepressants (recovery rates lower than 40%). These experiments demonstrated the selectivity of the developed MIP phase. The standardized method was linear in the range of 300 - 700 ng mL-1 for VEN, 5-700 ng mL-1 for ODV, and 3 to 500 ng mL-1 for NDV. Precision had coefficients of variation smaller than 15%; the accuracy standard error values ranged from -11.8 to 16.01%. Compared with literature methods, the developed method was more selective for determination of VEN and metabolites, required lower consumption of sample and organic solvents, and enabled reuse of the extraction phase. According to the assessed analytical validation parameters and to the analysis of samples obtained from patients undergoing therapy with VEN, the proposed method is suitable to determine VEN, NDV, and ODV in plasma samples for therapeutic drug monitoring.

Esta tese foi dividida em três capítulos. O capítulo I descreve o desenvolvimento do método Column switching UHPLC-MS/MS para a determinação simultaneamente de fármacos psicotrópicos em amostras de plasma de pacientes esquizofrênicos. A politerapia é uma prática comum no tratamento da esquizofrenia. Portanto, a monitorização terapêutica destes fármacos tem sido realizada para o ajuste das doses e individualização da terapia farmacológica. O método Column switching UHPLC-MS/MS apresentou linearidade na faixa de concentração de 0,025 a 1,25 ng mL-1 com R2 acima de 0,9950 e a falta de teste de ajuste (p > 0,05); precisão com coeficientes de variação inferiores a 12% e exatidão com erro padrão relativo inferior a 14%. Este método foi aplicado com sucesso para determinação de fármacos em amostras de plasma de pacientes esquizofrênicos para fins de monitorização terapêutica. No capítulo II, o desempenho cromatográfico de colunas C18 superficialmente e totalmente porosas com diferentes tamanhos de partícula foi avaliado para a análise de fármacos psicotrópicos por LC-MS/MS e LC-DAD. Com o sistema LC-MS/MS foram avaliados os seguintes parâmetros cromatográficos: altura do prato reduzido vs velocidade linear reduzida, impedância vs velocidade linear reduzida, tempo da corrida cromatográfica vs vazão, pressão vs vazão, resolução, capacidade de pico, assimetria e fator de retenção. Já com o sistema LC-DAD foram avaliados a hidrofobicidade, atividade silanol e impurezas metálicas também foram avaliadas. As colunas com superfície carregada apresentaram maior eficiência cromatográfica para os fármacos em sua forma ionizada. Já as colunas com partículas menores que 2 µm (Cortecs 1,6 µm, Acquity 1,7 µm, e Kinetex 1,7 µm) apresentaram maior eficiência cromatográfica para os fármacos na forma parcialmente ionizada. Os modelos matemáticos gerados foram capazes de prever a pressão e o tempo da corrida cromatográfica em diferentes vazões para todas as colunas. Considerando a eficiência, impedância, resolução, capacidade de pico, fator de retenção e hidrofobicidade, as colunas Cortecs 1,6 µm e Acquity 1,7 µm apresentaram melhor desempenho durante a análise dos fármacos em amostra de plasma. O capítulo III descreve o desenvolvimento e validação dos métodos SPME-UHPLC-MS/MS e Bio-SPME-Nano-ESI-MS/MS para a determinação dos endocanabinóides (AEA e 2-AG) em amostras biológicas. Para a otimização do processo SPME foram avaliadas as fases SPME (C18, C30 e HLB) e os solventes para dessorção (metanol, acetonitrila e isopropanol). Os aditivos modificadores de matriz, como cloridrato de guanidina, ácido trifluoroacético e acetonitrila foram avaliados por planejamento experimental. Os métodos SPME-UHPLC-MS/MS e Bio-SPME-Nano-ESI-MS/MS, com a fase HLB biocompatível, apresentaram para ambos endocanabinóides valores de LOQs de 1 ng mL-1 e 50 ng mL-1, respectivamente. O método Bio-SPME-Nano-ESI-MS/MS permitiu o direto acoplamento da fibra SPME ao espectrômetro de massas via dessorção/ionização nanoeletrospray que resultou em rápida determinação quantitativa dos endocanabinóides em amostras biológicas. / This thesis is divided into three chapters. Chapter I describes the development of a column switching UHPLCMS/MS method to determine psychotropic drugs in schizophrenic patients plasma samples simultaneously. Polytherapy is a common practice in schizophrenia treatment. Therefore, therapeutic drug monitoring has been applied to adjust doses and to customize pharmacological therapy. The column switching UHPLCMS/MS method developed here is linear at concentrations ranging from 0.025 to 1.25 ng mL-1 with R2 above 0.9950 and presents lack of fit test (p > 0.05), precision with coefficients of variation lower than 12%, and accuracy with relative standard error lower than 14%. This method was successfully applied to determine drugs in schizophrenic patients plasma samples for therapeutic drug monitoring. In chapter II, the chromatographic performance of C18 superficially porous columns and of C18 fully porous columns with different particle sizes were evaluated for analysis of psychotropic drugs by LC-MS/MS and LC-DAD. Within the LC-MS/MS system, the following chromatographic parameters were assessed: reduced plate height vs reduced linear velocity, impedance vs reduced linear velocity, chromatographic run time vs flow rate, backpressure vs flow rate, resolution, peak capacity, asymmetry, and retention factor. Within the LC-DAD system, hydrophobicity, silanol activity, and metal impurities were also examined. Columns with charged surface displayed improved chromatographic efficiency for drugs in the ionized form. Columns with particles smaller than 2 µm (Cortecs 1.6 µm, Acquity 1.7 µm, and Kinetex 1.7 µm) presented higher chromatographic efficiency for the drugs, which were in their partially ionized form. The generated mathematical models were able to predict the backpressure and the chromatographic run time at different flow rates for all the columns. Considering efficiency, impedance, resolution, peak capacity, retention factor, and hydrophobicity, columns Cortecs 1.6 µm and Acquity 1.7 µm provided the best performance during analysis of drugs in plasma samples. Chapter III describes the development and validation of the SPME-UHPLC-MS/MS and the Bio-SPME-Nano-ESI-MS/MS methods for determination of endocannabinoids (AEA and 2-AG) in biological samples. To optimize the SPME process, SPME coatings (C18, C30, and HLB) and solvents for desorption (methanol, acetonitrile, and isopropanol) were evaluated. Matrix modifier additives, such as guanidine hydrochloride, trifluoroacetic acid, and acetonitrile, were assessed by experimental design. The SPME-UHPC-MS/MS and the Bio-SPME-Nano-ESI-MS/MS methods with HLB biocompatible coating provided LOQ values of 1 ng mL-1 and 50 ng mL-1, respectively, for both endocannabinoids. The Bio-SPME-Nano-ESI-MS/MS method allowed direct coupling of SPME fibers to the mass spectrometer by desorption/ionization nanoelectrospray, which resulted in rapid quantitative determinations of endocannabinoids in biological samples.

Janus kinase 3 (JAK3) est un membre de la famille JAK de protéines tyrosine kinase impliquées dans la transduction du signal intracellulaire médiée par les récepteurs de cytokines via la voie de signalisation JAK/STAT. JAK3 s'est avéré exprimé de manière différentielle dans les cellules de la granulosa (GC) des follicules pré-ovulatoires bovins et régulé à la baisse par l'hormone lutéinisante. Ces observations suggèrent que la régulation de JAK3 pourrait moduler la prolifération des GC, l'activité stéroïdienne et l'activation/l'inhibition des cibles en aval. Pour étudier les mécanismes des actions de JAK3 dans GC, nous avons utilisé JANEX-1, un inhibiteur pharmacologique de JAK3, et des traitements FSH et analysé des marqueurs de prolifération, des enzymes stéroïdogènes et la phosphorylation de protéines cibles, y compris STAT3 et les partenaires JAK3 précédemment identifiés CDKN1B/p27Kip1 et MAPK8IP3/JIP3. Les GC en culture ont été traités avec ou sans FSH en présence ou non de JANEX-1. L'ARN total et les protéines ont été extraits et analysés par RT-qPCR, western blot et UHPLC-MS/MS. L'expression de l'enzyme stéroïdogène CYP11A1, mais pas du CYP19A1, était significativement régulée à la hausse dans les GC traités avec la FSH et les deux étaient significativement diminuées lorsque JAK3 était inhibé par rapport au contrôle. Les marqueurs de prolifération CCND2 et PCNA ont été significativement réduits dans les GC traités au JANEX-1 et régulés positivement par la FSH. Les analyses Western blots ont montré que le traitement JANEX-1 réduisait de manière significative les quantités de pSTAT3 tandis que la surexpression de JAK3 augmentait pSTAT3. De même, le traitement à la FSH a augmenté pSTAT3 même dans les GC traités au JANEX-1. Les analyses UHPLC-MS/MS ont montré une phosphorylation et des modifications supplémentaires de résidus d'acides aminés spécifiques dans JAK3 ainsi que ses partenaires de liaison CDKN1B et MAPK8IP3 révélant une activation ou une inhibition possible de JAK3 après des traitements FSH ou JANEX-1, respectivement. L'abondance de la protéine totale JAK3 a augmenté après le traitement par FSH et a diminué de manière significative, avec MAPK8IP3, dans le GC traité par JANEX-1, tandis que l'abondance totale de CDKN1B a été modifiée après FSH et augmentée après JANEX-1. Nous montrons que JAK3 influence l'activité GC par la phosphorylation de protéines cibles en réponse à des stimulations telles que la FSH, ce qui conduit à l'activation de JAK/STAT et module probablement d'autres voies de signalisation impliquant CDKN1B et MAPK8IP3. / Janus kinase 3 (JAK3) is a member of the JAK family of tyrosine kinase proteins involved in cytokine receptor-mediated intracellular signal transduction through the JAK/STAT signaling pathway. JAK3 was shown as differentially expressed in granulosa cells (GC) of bovine preovulatory follicles and downregulated by the luteinizing hormone. These observations suggested JAK3 regulation could modulate GC proliferation, steroidogenic activity and activation/inhibition of downstream targets. To investigate the mechanisms of JAK3 actions in GC, we used JANEX-1, a pharmacological JAK3 inhibitor, and FSH treatments and analyzed proliferation markers, steroidogenic enzymes and phosphorylation of target proteins including STAT3 and previously identified JAK3 partners CDKN1B/p27Kip1 and MAPK8IP3/JIP3. Cultured GCs were treated with or without FSH in the presence or not of JANEX-1. Total RNA and proteins were extracted and analyzed by RT-qPCR, western blotting and UHPLC-MS/MS. Expression of steroidogenic enzyme CYP11A1, but not CYP19A1, was significantly upregulated in GC treated with FSH and both were significantly decreased when JAK3 was inhibited as compared to control. Proliferation markers CCND2 and PCNA were significantly reduced in JANEX-1-treated GC and upregulated by FSH. Western blots analyses showed that JANEX-1 treatment significantly reduced pSTAT3 amounts while JAK3 overexpression increased pSTAT3. Similarly, FSH treatment increased pSTAT3 even in JANEX-1-treated GC. UHPLC-MS/MS analyses showed phosphorylation and additional modifications of specific amino acid residues within JAK3 as well as its binding partners CDKN1B and MAPK8IP3 revealing possible activation or inhibition of JAK3 following FSH or JANEX-1 treatments, respectively. Abundance of JAK3 total protein was increased post-FSH treatment and significantly decreased, along with MAPK8IP3, in JANEX-1-treated GC while CDKN1B total abundance was altered post-FSH and increased post-JANEX-1. We show that JAK3 influences GC activity through phosphorylation of target proteins in response to stimulations such as FSH, which leads to the activation of JAK/STAT and likely modulating other signaling pathways involving CDKN1B and MAPK8IP3.